phenylacetic acid

Trade name: ucephan

Small moleculeapprovedOrphan Drug FDA

Approved

Jul 1, 1987

Phenylacetic acid (abr. PAA and synonyms are: α-toluic acid, benzeneacetic acid, alpha tolylic acid, 2-phenylacetic acid, β-phenylacetic acid) is an organic compound containing a phenyl functional group and acarboxylic acid functional group. Because it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China Phenylacetic acid is used in some perfumes, possessing a honey-like odor in low concentrations, and is also used in penicillin G production. It is also employed to treat type II hyperammonemia to help reduce the amounts of ammonia in a patient's bloodstream by forming phenylacetyl-CoA, which then reacts with nitrogen-rich glutamine to form phenylacetylglutamine. This compound is then secreted by the patient's body. In Phase 2 of clinical research it investigated in the treatment of Brain and Central Nervous System Tumors. — NCATS

Clinical trial activity

47 trials · 7 clinical orgs · 7 marketing orgs

Phase 1
1
Phase 2
46
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 1985 (NCT00004767)

Timeline

1980s

  1. Jan 1, 1985

    Earliest Phase 2 Sponsor(trial)

  2. Jan 21, 1986

    Orphan Drug Designation

  3. Jul 1, 1987

    Earliest FDA Approval

  4. Dec 23, 1987

    Kendall McGaw Laboratories — First NDA Organization

  5. Dec 23, 1987

    B. Braun — NDA Secondary Org

  6. Dec 23, 1987

    Kendall McGaw Laboratories — NDA Organization

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  2. Feb 17, 2005

    Medicis — NDA Secondary Org

  3. Feb 17, 2005

    Bausch Health Companies — NDA Secondary Org

2010s

  1. Feb 24, 2016

    Ailex Pharmaceuticals — Marketing Organization

  2. Aug 4, 2016

    Navinta — Marketing Organization

  3. May 8, 2017

    Maia Pharms Inc — Marketing Organization

2020s

  1. Jun 10, 2021

    Maia Pharms Inc — NDA Secondary Org

Indications

Mechanism of action

  • GlutamineSEQUESTERING AGENT

    Glutamine sequestering agent

    Removes excess nitrogen, caused by enzyme deficiency

Combination products

Approval history

  • approvedJul 1, 1987

Chemistry & pharmacology

Loading structure…

SMILES

OC(=O)CC1=CC=CC=C1
Mol. weight
136.1479 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • benzeneacetic acid
  • benzeneacetic acid
  • benzeneacetic acid
  • benzeneacetic acid
  • benzeneacetic acid
  • phenylacetate
  • phenylacetate
  • phenylacetate
  • phenylacetate
  • phenylacetic acid
  • phenylacetic acid
  • phenylacetic acid
  • phenylacetic acid
  • phenylacetic acid, ammonium salt
  • phenylacetic acid, calcium salt
  • phenylacetic acid, cesium salt
  • phenylacetic acid, lithium salt
  • phenylacetic acid, mercury salt
  • phenylacetic acid, potassium salt
  • phenylacetic acid, rubidium salt
  • phenylacetic acid, sodium salt
  • phenylacetic acid, sodium salt , carboxy-(11)c-labeled cpd
  • phenylethanoic acid
  • sodium phenylacetate
  • sodium phenylacetate
  • sodium phenylacetate
  • sodium phenylacetate
  • sodium phenylacetate
  • ucephan
  • ucephan

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00597909Phase 2Dec 1, 2007Horizon Pharma
NCT00977600Phase 1Mar 1, 2005Horizon Pharma, Ucyclyd
NCT00003455Phase 2Nov 1, 1999Burzynski Research Institute
NCT00003502Phase 2Nov 1, 1999Burzynski Research Institute
NCT00003517Phase 2Nov 1, 1999Burzynski Research Institute
NCT00003505Phase 2Nov 1, 1999Burzynski Research Institute
NCT00003514Phase 2Nov 1, 1999Burzynski Research Institute
NCT00003486Phase 2Nov 1, 1999Burzynski Research Institute
NCT00003456Phase 2Nov 1, 1998Burzynski Research Institute
NCT00003471Phase 2Aug 1, 1998Burzynski Research Institute
NCT00003491Phase 2Aug 1, 1998Burzynski Research Institute
NCT00003489Phase 2Aug 1, 1998Burzynski Research Institute
NCT00003512Phase 2Aug 1, 1998Burzynski Research Institute
NCT00003494Phase 2Aug 1, 1998Burzynski Research Institute
NCT00003500Phase 2Aug 1, 1998Burzynski Research Institute
NCT00003501Phase 2Aug 1, 1998Burzynski Research Institute
NCT00003485Phase 2Aug 1, 1998Burzynski Research Institute
NCT00003497Phase 2Aug 1, 1998Burzynski Research Institute
NCT00003496Phase 2Aug 1, 1998Burzynski Research Institute
NCT00003495Phase 2Aug 1, 1998Burzynski Research Institute
Showing 20 of 47 trials
Page 1 / 3

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Burzynski Research InstituteAcademic/Hospital434311993
Horizon PharmaFor profit2222005
Baylor UniversityAcademic/Hospital1111998
Johns Hopkins UniversityAcademic/Hospital1011985
National Cancer Institute (NCI)Government1011998
National Center for Research Resources (NCRR)Government1111985
UcyclydFor profit1012005
7 organizations
Page 1 / 1

Marketing (8)

OrganizationOrg typeRelationshipDate
Ailex PharmaceuticalsFor profitMKTGFeb 24, 2016
B. BraunFor profitNDA2Dec 23, 1987
Bausch Health CompaniesFor profitNDA2Feb 17, 2005
Kendall McGaw LaboratoriesFor profitNDADec 23, 1987
Maia Pharms IncFor profitMKTGMay 8, 2017
Maia Pharms IncFor profitNDA2Jun 10, 2021
MedicisFor profitNDA2Feb 17, 2005
NavintaFor profitMKTGAug 4, 2016